BioAgilytix (NC, USA), a provider of large-molecule bioanalytical testing services, has announced the acquisition of the Boston-based CRO, Cambridge Biomedical (MA, USA), which also specializes in large-molecule bioanalysis.
Researchers have analyzed flotillin levels in samples from individuals with and without Alzheimer’s disease (AD) and determined that serum flotillin levels are negatively associated with brain amyloid deposition. Flotillin could serve as a biomarker to estimate brain amyloid deposition, potentially aiding the early diagnosis of AD.
Novel artificial intelligence tool could revolutionize bioanalytical data review for precision drug development
Specialist in artificial intelligence-enabled solutions, Ariadne Software (PA, USA), announces the launch of Red Thread™, an innovative tool that could revolutionize bioanalytical data review for precision drug development.
In a pilot study, researchers from the School of Medicine at the University of Nottingham (UK), report the use of protein microarrays to rapidly screen blood samples for the presence of autoantibodies associated with breast cancer.
Researchers from the University of Bath (UK) have reported a prototype test that could detect whether an individual has recently taken ‘spice’ – a synthetic street drug – in under 5 minutes.
Researchers from the RIKEN Center for Brain Science (Wako, Japan) have identified that hydrogen sulfide production – as a result of MPST gene expression – was higher in postmortem brains from individuals with schizophrenia compared with unaffected individuals.
Scientists from the University of California San Diego (CA, USA) and the University of Alcalá (Madrid, Spain) have reported a pacifier biosensor that could pave the way for future research towards noninvasive saliva biomarker monitoring.
Researchers have reported a new blood test that could accurately identify and distinguish active cases of tuberculosis in adults from diseases with similar symptoms in under 1 hour.
Researchers report a diagnostic tool that analyses the risk factors for preterm birth, results indicated approximately 10% of women from 340 vaginal fluid samples analyzed were at risk. This diagnostic tool could reduce the likelihood of premature delivery.
Thermo Fisher Scientific (MA, USA) have announced a new molecular quality control panel. The panel could provide researchers with increased confidence when performing BCR-ABL assays.